Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW; HORIZONS-AMI Trial Investigators.

Lancet. 2009 Oct 3;374(9696):1149-59. doi: 10.1016/S0140-6736(09)61484-7. Epub 2009 Aug 28.

PMID:
19717185
2.

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

Shah A, Feldman DN.

Vasc Health Risk Manag. 2012;8:115-23. doi: 10.2147/VHRM.S23491. Epub 2012 Feb 27. Review.

3.

Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.

Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, Feldman DN.

Am J Cardiol. 2014 Jul 15;114(2):250-9. doi: 10.1016/j.amjcard.2014.04.033. Epub 2014 May 2. Review.

PMID:
24890986
4.

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.

Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JP, Bakhai A.

Pharmacoeconomics. 2013 Apr;31(4):269-75. doi: 10.1007/s40273-013-0036-7. Review.

PMID:
23512147
6.

Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.

Nairooz R, Sardar P, Amin H, Chatterjee S, Helmy T, Naidu SS.

Catheter Cardiovasc Interv. 2015 Sep;86(3):364-75. doi: 10.1002/ccd.25952. Epub 2015 Apr 24. Review.

PMID:
25914388
7.

How to reduce mortality in ST-elevation myocardial infarction patients treated with primary percutaneous coronary interventions: cut the bleeding.

De Servi S, Mariani G, Mariani M, D'Urbano M.

Curr Med Res Opin. 2013 Mar;29(3):189-94. doi: 10.1185/03007995.2013.770389. Epub 2013 Jan 31. Review.

PMID:
23350949
8.

Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial.

Capranzano P, Dangas G.

Expert Rev Cardiovasc Ther. 2012 Apr;10(4):411-22. doi: 10.1586/erc.12.24. Review.

PMID:
22458574
9.

Bivalirudin: in patients with ST-segment elevation myocardial infarction.

Curran MP.

Drugs. 2010 May 7;70(7):909-18. doi: 10.2165/11205120-000000000-00000. Review.

PMID:
20426499
10.

Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.

Faulkenberg KD, Beavers JC, Finks SW.

Ann Pharmacother. 2016 Feb;50(2):141-51. doi: 10.1177/1060028015618206. Epub 2015 Dec 17. Review.

PMID:
26681442
11.

An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.

Shah R, Rogers KC, Matin K, Askari R, Rao SV.

Am Heart J. 2016 Jan;171(1):14-24. doi: 10.1016/j.ahj.2015.10.006. Epub 2015 Oct 20. Review.

PMID:
26699596
12.

Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis.

Huang FY, Huang BT, Peng Y, Liu W, Zhao ZG, Wang PJ, Zuo ZL, Zhang C, Liao YB, Luo XL, Meng QT, Chen C, Huang KS, Chai H, Li Q, Chen M, Zhu Y.

Angiology. 2015 Oct;66(9):845-55. doi: 10.1177/0003319715568972. Epub 2015 Jan 29. Review.

PMID:
25635117
13.

Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis.

Li J, Yu S, Qian D, He Y, Jin J.

Medicine (Baltimore). 2015 Aug;94(32):e1067. doi: 10.1097/MD.0000000000001067. Review.

14.

Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?

Mahmoud A, Saad M, Elgendy AY, Abuzaid A, Elgendy IY.

Cardiovasc Ther. 2015 Aug;33(4):227-35. doi: 10.1111/1755-5922.12124. Review.

PMID:
25879426
15.

Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials.

Keeley EC, Boura JA, Grines CL.

Lancet. 2006 Feb 18;367(9510):579-88. Review. Erratum in: Lancet. 2006 May 20;367(9523):1656.

PMID:
16488801
16.

The Ideal Anticoagulation Strategy in ST-Elevation Myocardial Infarction.

Chandrasekhar J, Mehran R.

Prog Cardiovasc Dis. 2015 Nov-Dec;58(3):247-59. doi: 10.1016/j.pcad.2015.08.007. Epub 2015 Aug 7. Review.

PMID:
26260610
17.

Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention.

Barria Perez AE, Rao SV, Jolly SJ, Pancholy SB, Plourde G, Rimac G, Poirier Y, Costerousse O, Bertrand OF.

Am J Cardiol. 2016 Apr 15;117(8):1256-66. doi: 10.1016/j.amjcard.2016.01.015. Epub 2016 Jan 28. Review.

PMID:
26899489
18.

Bivalirudin for acute coronary syndromes: premises, promises and doubts.

Capodanno D, De Caterina R.

Thromb Haemost. 2015 Apr;113(4):698-707. doi: 10.1160/TH14-09-0765. Epub 2014 Dec 18. Review.

PMID:
25519159
19.

Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.

Zhang S, Gao W, Li H, Zou M, Sun S, Ba Y, Liu Y, Cheng G.

Int J Cardiol. 2016 Apr 15;209:87-95. doi: 10.1016/j.ijcard.2016.01.206. Epub 2016 Jan 26. Review.

PMID:
26882192
20.

Re-infarction after primary percutaneous coronary intervention.

French JK, Burgess S, Chew DP.

Curr Opin Cardiol. 2015 Jul;30(4):354-8. doi: 10.1097/HCO.0000000000000193. Review.

PMID:
26049380
Items per page

Supplemental Content

Write to the Help Desk